Browse > Article
http://dx.doi.org/10.22889/KJP.2022.53.2.64

Anti-aggregation Effect of Artemether Through Regulation of PI3K/Akt and MAPK in U46619-induced Platelets  

Park, Chang-Eun (Department of Biomedical Laboratory Science, Molecular Diagnostics Research Institute, Namseoul University)
Lee, Dong-Ha (Department of Biomedical Laboratory Science, Molecular Diagnostics Research Institute, Namseoul University)
Publication Information
Korean Journal of Pharmacognosy / v.53, no.2, 2022 , pp. 64-69 More about this Journal
Abstract
When blood vessels are damaged, a rapid hemostatic response should occur in order to lower blood loss and keep normal circulation, and platelet activation and aggregation are essential. Nevertheless, abnormal or excessive platelet aggregation can be a reason of cardiovascular diseases including thrombosis, atherosclerosis, and stroke. Therefore, the screening for a substance which can regulate platelet activation and suppress aggregation reaction is very important for treatment and prevention of cardiovascular diseases. Artemether is a methyl ether derivative of artemisinin, which is isolated from the antimalarial plant Artemisia annua, but research on platelet aggregation or its mechanisms is still insufficient. This study identified the effects of artemether on U46619-induced human platelet aggregation and their granule secretion (ATP and serotonin release). In addition, the effects of artemether on the phosphorylation of PI3K/Akt or MAPK, which are related to signal transduction in platelet aggregation, were studied. As the results, artemether significantly lowered PI3K/Akt and MAPK phosphorylation, which inhibited platelet aggregation through granule secretion (ATP and serotonin release) dose-dependently. Therefore, we suggest that artemether is an antiplatelet substance that regulates PI3K/Akt and MAPK pathway and is of value as a therapeutic and preventive agent for platelet-derived cardiovascular diseases.
Keywords
Artemether; PI3K/Akt; MAPK; ATP; Serotonin;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Payrastre, B., Missy, K., Trumel, C., Bodin, S., Plantavid, M. and Chap, H. (2000) The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem. Pharmacol. 60: 1069-1074.   DOI
2 Jackson, S. P. (2011) Arterial thrombosis?insidious, unpredictable and deadly. Nat. Med. 17: 1423-1436.   DOI
3 Schwartz, S. M., Heimark, R. L. and Majesky, M. W. (1990) Developmental mechanisms underlying pathology of arteries. Physiol. Rev. 70: 1177-1209.   DOI
4 Phillips, D. R., Nannizzi-Alaimo, L. and Prasad, K. S. (2001) Beta3 tyrosine phosphorylation in alphaIIbbeta3 (platelet membrane GP IIb-IIIa) outside-in integrin signaling. Thromb. Haemost. 86: 246-258.   DOI
5 Morello, F., Perino, A. and Hirsch, E. (2009) Phosphoinositide 3-kinase esculetin in the vascular system. Cardiovasc. Res. 82: 261-271.   DOI
6 Jennings, L. K. (2009) Role of platelets in atherothrombosis. Am. J. Cardiol. 103: 4A-10A.   DOI
7 Sabatine, M. S. and Jang, I. K. (2000) The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am. J. Med. 109: 224-237.   DOI
8 Cattanco, M., Tenconi, P. M., Lecchi, A. and Mannucci, P. M. (1991) In vitro effects of picotamide on human platelet aggregation, the release re- action and thromboxane B2 production. Thromb. Res. 62: 717-724.   DOI
9 Su, C. Y., Shiao, M. S. and Wang, C. T. (1999) Differential effects of ganodermic acid S on the thromboxane A2-signaling pathways in human platelets. Biochem. Pharmacol. 58: 587-595.   DOI
10 Bugaud, F., Nadal-Wollbold, F., Levy-Toledano, S., Rosa, J. P. and Bryckaert, M. (1990) Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood 94: 3800-3805.   DOI
11 Kramer, R. M., Roberts, E. F., Strifler, B. A. and Johnstone, E. M. (1995) Thrombin induces activation of p38 MAP kinase in human platelets. J. Biol. Chem. 270: 27395-27398.   DOI
12 Nadal-Wollbold, F., Pawlowski, M., Levy-Toledano, S., Berrou, E., Rosa, J. P. and Bryckaert, M. (2002) Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett. 531: 475-482.   DOI
13 Patrono, C. (1994) Aspirin as an antiplatelet drug. N. Engl. J. Med. 330: 1287-1294.   DOI
14 Adam, F., Kauskot, A., Rosa, J. P. and Bryckaert, M. (2008) Mitogen activated protein kinases in hemostasis and thrombosis. J. Thromb. Haemost. 6: 2007-2016.   DOI
15 Flevaris, P., Li, Z., Zhang, G., Zheng, Y., Liu, J. and Du, X. (2009) Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 13: 893-901.
16 Chuang, W. Y., Kung, P. H., Kuo, C. Y. and Wu, C. C. (2013) Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway. Thromb. Haemost. 109: 1120-1130.   DOI
17 Esu, E. B., Effa, E. E., Opie, O. N. and Meremikwu, M. M. (2019). Artemether for severe malaria, Cochrane Database Syst. Rev. 6: CD010678.
18 Irfan, M., Jeong, D., Saba, E., Kwon, H. W., Shin, J. H., Jeon, B. R., Kim, S., Kim, S. D., Lee, D. H., Nah, S. Y. and Rhee, M. H. (2019) Gintonin modulates platelet function and inhibits thrombus formation via impaired glycoprotein VI signaling. Platelets 30: 589-598.   DOI
19 Saeed, M. E., Krishna, S., Greten, H. J., Kremsner, P. G. and Efferth, T. (2016) Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacological. Research. 110: 216-226.   DOI
20 Shin, J. H., Kwon, H. W. and Lee, D. H. (2019) Ginsenoside F4 inhibits platelet aggregation and thrombus formation by dephosphorylation of IP3RI and VASP. J. Appl. Biol. Chem. 62: 93-100.   DOI
21 McNicol, A. and Jackson, E. C. (2003) Inhibition of the MEK/ERK pathway has no effect on agonist-induced aggregation of human platelets. Biochem. Pharmacol. 65: 1243-1250.   DOI